<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Newsroom

News

External stories on biodesix

Posts in: NSCLC

GenomeWeb: Biodesix Sees Expansion into Genomics Driving Adoption of VeriStrat Proteomic Test

Adoption of GeneStrat by oncologists is helping to drive greater adoption of VeriStrat, Biodesix's proteomic test for assessing a patient's prognosis and predicting response to drug treatment.

AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress

Results from a analysis suggest VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone.

Biodesix’s VeriStrat Test for Cancer Treatment Passes Phase 3 Trial (Xconomy)

Veristart passed a key clinical trial that shows it can give physicians a better idea of what to do next after the first round of treatment for NSCLC.

Putting Lung Cancer in the Bullseye (Breakthroughs)

Lung cancer specialist Karen Reckamp, M.D., is tired of seeing what the disease does to her patients. It all comes down to a blood test called VeriStrat.

Biodesix Feels the Buzz at BIO2012 (FierceBiomarkers)

Biodesix’s business model is based on two strands–clinical diagnostics and companion diagnostics; Tests based on the presence or absence of a biomarker.

A Test to Go With It (GenomeWeb)

Pharmaceutical companies are increasingly turning to companion diagnostic tests to determine whether a drug is suitable for a given patient.

Charting a Course for Progress Institute of Medicine Report Calls for Rigor and Standardization (The Burrill Report)

Biodesix's Jeffrey Bojar discusses Evolution of Translational Omics: Lessons Learned and the Path Forward and the rigorous framework it provides.

A Better Route for Diagnostics? (Drug Discovery & Development)

The Human Genome Project was expected to yield substantial benefits in diagnostics. But the genome is only part of the story. mRNA are equally as important.

Protein Test Found to Boost NSCLC Survival, Costs (MedPage Today)

Choosing second-line therapy on the basis of a protein-expression test modestly improved survival in patients with advanced non-small cell lung cancer.

Trial Shows Biodesix Assay Predicts Breast Cancer Response to Femara (Genetic Engineering News)

Trial Shows Biodesix Assay Predicts Breast Cancer Response to Femara (Genetic Engineering News)

1 2 Last